KR960033471A - 나노현탁액용 제약 담체 - Google Patents
나노현탁액용 제약 담체 Download PDFInfo
- Publication number
- KR960033471A KR960033471A KR1019960007541A KR19960007541A KR960033471A KR 960033471 A KR960033471 A KR 960033471A KR 1019960007541 A KR1019960007541 A KR 1019960007541A KR 19960007541 A KR19960007541 A KR 19960007541A KR 960033471 A KR960033471 A KR 960033471A
- Authority
- KR
- South Korea
- Prior art keywords
- water
- alkyl
- substituted
- carboxy
- amino
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q10/00—Administration; Management
- G06Q10/08—Logistics, e.g. warehousing, loading or distribution; Inventory or stock management
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
- G06K19/00—Record carriers for use with machines and with at least a part designed to carry digital markings
- G06K19/06—Record carriers for use with machines and with at least a part designed to carry digital markings characterised by the kind of the digital marking, e.g. shape, nature, code
- G06K19/067—Record carriers with conductive marks, printed circuits or semiconductor circuit elements, e.g. credit or identity cards also with resonating or responding marks without active components
- G06K19/07—Record carriers with conductive marks, printed circuits or semiconductor circuit elements, e.g. credit or identity cards also with resonating or responding marks without active components with integrated circuit chips
- G06K19/0723—Record carriers with conductive marks, printed circuits or semiconductor circuit elements, e.g. credit or identity cards also with resonating or responding marks without active components with integrated circuit chips the record carrier comprising an arrangement for non-contact communication, e.g. wireless communication circuits on transponder cards, non-contact smart cards or RFIDs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Business, Economics & Management (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Economics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- General Physics & Mathematics (AREA)
- Theoretical Computer Science (AREA)
- Biophysics (AREA)
- Marketing (AREA)
- Heart & Thoracic Surgery (AREA)
- Human Resources & Organizations (AREA)
- Entrepreneurship & Innovation (AREA)
- Operations Research (AREA)
- General Business, Economics & Management (AREA)
- Tourism & Hospitality (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Strategic Management (AREA)
- Development Economics (AREA)
- Cardiology (AREA)
- Quality & Reliability (AREA)
Abstract
본 발명은 약간 가용성인 스타우로스포린 유도체, N-벤조일-스타우로스포린을 정맥내 투여하기 위한 제약 조성물의 제조용 제형 기제에 관한 것이다. 이 조성물은 다음의 바람직한 성분으로 이루어진다 : a) 치료제인 스타우로스포린 유도체, b) 폴리옥시에틸렌/폴리옥시프로필렌 블록 공중합체, c) 담체 액체로서의 에탄올 및 물, d) 대두로부터 정제된 레시틴, 및 e) 수가용성 부형제로서의 글리세롤 및 소르비톨.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (2)
- b) 폴리옥시에틸렌/폴리옥시프로필렌 블록 공중합체, c) 정맥내 투여를 위한 처방 순도를 갖는, 담체 액체로서의 에탄올 및 물, 및 임으로 d) 하기 일반식의 인지질 또는 이러한 화합물의 염, 및(또는) e) 수가용성 부형제로서 글리세롤 및 제약상 허용되는 육탄당을 포함하는 제형 기제.상기 식 중, R1은 C10-20아실이고, R2는 수소 또는 C10-20아실이며, R3은 수소, 2-트리메틸아미노-1-에틸, 2-아미노-1-에틸, C1-4알킬, 카르복시에 치환된 C1-5알킬, 히드록시에 의해 치환된 C2-5알킬, 카르복시 및 히드록시에 의해 치환된 C2-5알킬, 카르복시 및 아미노에 의해 치환된 C2-5알킬, 또는 이노시톨기 또는 글리세릴기이다.
- 제1항에 있어서, b) 폴리옥시에틸렌/폴리옥시프로필렌 블록 공중합체, c) 담체 액체로서의 에탄올 및 물, d) 대두로부터 정제된 레시틴, 및(또는) e) 수가용성 부형제로서의 글리세롤 및 소르비톨을 포함하는 제약 조성물.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH804/95 | 1995-03-21 | ||
CH80495 | 1995-03-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR960033471A true KR960033471A (ko) | 1996-10-22 |
Family
ID=4195580
Family Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019960007552A KR960034028A (ko) | 1995-03-21 | 1996-03-20 | 저온 캡슐 및 저온 캡슐이 내장된 용기 |
KR1019960007541A KR960033471A (ko) | 1995-03-21 | 1996-03-20 | 나노현탁액용 제약 담체 |
KR1019960007484A KR100191221B1 (ko) | 1995-03-21 | 1996-03-20 | 공중전화망(pstn)에 이용되는 팩스/데이터/음성 다기능 지원 장치 및 그 방법 |
KR1019960007547A KR960035462A (ko) | 1995-03-21 | 1996-03-20 | 다중 광디스크 구동 장치 및 방법 |
KR1019960007485A KR100191219B1 (ko) | 1995-03-21 | 1996-03-20 | 실리콘 웨이퍼 제조 공장 폐수의 효율적인 처리 방법 |
KR1019960007540A KR960033470A (ko) | 1995-03-21 | 1996-03-20 | 정맥내 투여용 나노현탁액 |
KR1019960007545A KR100194987B1 (ko) | 1995-03-21 | 1996-03-20 | 입출 감시 시스템 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019960007552A KR960034028A (ko) | 1995-03-21 | 1996-03-20 | 저온 캡슐 및 저온 캡슐이 내장된 용기 |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019960007484A KR100191221B1 (ko) | 1995-03-21 | 1996-03-20 | 공중전화망(pstn)에 이용되는 팩스/데이터/음성 다기능 지원 장치 및 그 방법 |
KR1019960007547A KR960035462A (ko) | 1995-03-21 | 1996-03-20 | 다중 광디스크 구동 장치 및 방법 |
KR1019960007485A KR100191219B1 (ko) | 1995-03-21 | 1996-03-20 | 실리콘 웨이퍼 제조 공장 폐수의 효율적인 처리 방법 |
KR1019960007540A KR960033470A (ko) | 1995-03-21 | 1996-03-20 | 정맥내 투여용 나노현탁액 |
KR1019960007545A KR100194987B1 (ko) | 1995-03-21 | 1996-03-20 | 입출 감시 시스템 |
Country Status (12)
Country | Link |
---|---|
US (1) | US5726164A (ko) |
EP (2) | EP0733358A3 (ko) |
JP (2) | JPH08268893A (ko) |
KR (7) | KR960034028A (ko) |
AU (2) | AU4809596A (ko) |
CA (2) | CA2172110A1 (ko) |
HU (2) | HUP9600701A3 (ko) |
IL (2) | IL117551A0 (ko) |
MX (1) | MX9601032A (ko) |
NO (2) | NO961136L (ko) |
NZ (2) | NZ286207A (ko) |
ZA (2) | ZA962248B (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100422763B1 (ko) * | 2002-01-17 | 2004-03-12 | 주식회사 태평양 | 경피흡수 촉진 능력이 우수한 식물성 나노입자의 제조 및이를 함유하는 화장료 및 의약용 외용제 조성물 |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0733358A3 (de) * | 1995-03-21 | 1998-05-20 | Novartis AG | Intravenös applizierbare Nanosuspensionen |
US6066602A (en) * | 1997-08-07 | 2000-05-23 | Becton Dickinson And Company | Waterborne non-silicone lubricant comprising phospholipid and polyether |
US6711160B2 (en) * | 1998-03-31 | 2004-03-23 | International Business Machines Corporation | Packet network telephone interface system for POTS |
TWI241915B (en) * | 1998-05-11 | 2005-10-21 | Ciba Sc Holding Ag | A method of preparing a pharmaceutical end formulation using a nanodispersion |
US7795246B2 (en) * | 1998-08-06 | 2010-09-14 | Cephalon, Inc. | Particle-forming compositions containing fused pyrrolocarbazoles |
US6200968B1 (en) * | 1998-08-06 | 2001-03-13 | Cephalon, Inc. | Particle-forming compositions containing fused pyrrolocarbazoles |
KR100660529B1 (ko) * | 1999-01-07 | 2006-12-22 | 삼성전자주식회사 | 통신 시스템 및 그의 제어 방법 |
GB9903547D0 (en) * | 1999-02-16 | 1999-04-07 | Novartis Ag | Organic compounds |
JP3653422B2 (ja) * | 1999-08-20 | 2005-05-25 | シャープ株式会社 | 排水処理方法および排水処理装置 |
US6191121B1 (en) * | 2000-04-06 | 2001-02-20 | Nicholas V. Perricone | Treatment of skin damage using polyenylphosphatidylcholine |
US6979459B1 (en) | 2000-04-06 | 2005-12-27 | Perricone Nicholas V | Treatment of skin damage using polyenylphosphatidycholine |
US6932963B2 (en) | 2000-06-23 | 2005-08-23 | Nicholas V. Perricone | Treatment of skin wounds using polyenylphosphatidylcholine and alkanolamines |
US6623765B1 (en) * | 2000-08-01 | 2003-09-23 | University Of Florida, Research Foundation, Incorporated | Microemulsion and micelle systems for solubilizing drugs |
KR20020065105A (ko) * | 2001-02-05 | 2002-08-13 | 동안엔지니어링 주식회사 | 반도체 세정폐수 중 절삭가공 폐수에서 농축, 회수된실리콘 입자의 재활용 방법 |
ES2261671T3 (es) * | 2001-03-26 | 2006-11-16 | Novartis Ag | Mezcla farmaceutica que incluye una estaurosporina poco soluble en agua, un surfactante y un polimero soluble en agua. |
KR20090087139A (ko) * | 2001-10-30 | 2009-08-14 | 노파르티스 아게 | Flt3 수용체 티로신 키나아제 활성의 억제제로서의 스타우로스포린 유도체 |
US20040018237A1 (en) * | 2002-05-31 | 2004-01-29 | Perricone Nicholas V. | Topical drug delivery using phosphatidylcholine |
US8435942B2 (en) * | 2002-05-31 | 2013-05-07 | Transdermal Biotechnology, Inc. | Methods for formulating stabilized insulin compositions |
DE10233737A1 (de) * | 2002-07-24 | 2004-02-05 | Morphochem Aktiengesellschaft für kombinatorische Chemie | Verwendung von Modulatoren des Signaltransduktionswegs über die Proteinkinase Fyn zur Behandlung von Tumorerkrankungen |
JP2007501774A (ja) | 2003-08-08 | 2007-02-01 | ノバルティス アクチエンゲゼルシャフト | スタウロスポリンを含む組み合わせ |
DE102004019413A1 (de) * | 2004-04-19 | 2005-11-24 | Phenos Gmbh | Hemmung der Proteinkinase C epsilon zur Behandlung von Krankheiten |
KR20050102711A (ko) * | 2004-04-21 | 2005-10-27 | 서울통신기술 주식회사 | 아이 브이 알 시스템에서의 신호처리장치 및 그 방법 |
MX2007001155A (es) * | 2004-07-29 | 2007-08-14 | Creabilis Therapeutics Spa | Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1. |
US20090155352A1 (en) * | 2007-11-20 | 2009-06-18 | Cephalon, Inc. | Microemulsion containing indolocarbazole compound and dosage forms containing the same |
US9005597B2 (en) * | 2008-10-30 | 2015-04-14 | Medlite A/S | Formulation for treatment of vaginal dryness |
WO2011000811A2 (en) * | 2009-06-30 | 2011-01-06 | Novartis Ag | Organic compounds |
EP2335686A1 (en) * | 2009-12-21 | 2011-06-22 | LEK Pharmaceuticals d.d. | An aqueous intravenous nanosuspension with reduced adverse effects |
CA2830298C (en) | 2011-03-17 | 2016-08-16 | Transdermal Biotechnology, Inc. | Topical nitric oxide systems comprising lecithin and methods of use thereof |
MX2014013411A (es) * | 2012-05-29 | 2015-10-09 | Becton Dickinson France | Revestimiento lubricante y dispositivo de inyeccion medico que comprende dicho revestimiento. |
US8871261B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Cancer treatments and compositions for use thereof |
US8871257B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery |
US8871258B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Treatment and prevention of learning and memory disorders |
US8871255B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Treatment of skin and soft tissue infection with nitric oxide |
US8871260B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Methods and compositions for muscular and neuromuscular diseases |
US8871256B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Methods and systems for treatment of inflammatory diseases with nitric oxide |
US8871254B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system |
US8871262B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Compositions and methods for treatment of osteoporosis and other indications |
US8871259B2 (en) | 2012-09-19 | 2014-10-28 | Transdermal Biotechnology, Inc. | Techniques and systems for treatment of neuropathic pain and other indications |
US9387159B2 (en) | 2013-03-13 | 2016-07-12 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
US20140271937A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Brain and neural treatments comprising peptides and other compositions |
US9314422B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
US9750787B2 (en) | 2013-03-13 | 2017-09-05 | Transdermal Biotechnology, Inc. | Memory or learning improvement using peptide and other compositions |
US9295647B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
US9393265B2 (en) | 2013-03-13 | 2016-07-19 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
US20140271731A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
US9314417B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
US9393264B2 (en) | 2013-03-13 | 2016-07-19 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
US9724419B2 (en) | 2013-03-13 | 2017-08-08 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
US9320706B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
US20140271938A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
US9295637B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Compositions and methods for affecting mood states |
US9314433B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
US9295636B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
US9241899B2 (en) | 2013-03-13 | 2016-01-26 | Transdermal Biotechnology, Inc. | Topical systems and methods for treating sexual dysfunction |
US9314423B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Hair treatment systems and methods using peptides and other compositions |
US9339457B2 (en) | 2013-03-13 | 2016-05-17 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
US9320758B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Brain and neural treatments comprising peptides and other compositions |
US9849160B2 (en) | 2013-03-13 | 2017-12-26 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
US9687520B2 (en) | 2013-03-13 | 2017-06-27 | Transdermal Biotechnology, Inc. | Memory or learning improvement using peptide and other compositions |
WO2016024595A1 (ja) * | 2014-08-11 | 2016-02-18 | 国立大学法人東京大学 | エピルビシン複合化ブロック共重合体と、抗癌剤とを含むミセル、及び当該ミセルを含む癌又は耐性癌、転移癌の治療に適用可能な医薬組成物 |
EP3319608A4 (en) * | 2015-07-07 | 2019-04-03 | LifeRaft Biosciences, Inc. | POLOXAMER 188 FORMULATIONS WITH REDUCED SODIUM AND METHOD OF USE |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4431631A (en) * | 1983-01-03 | 1984-02-14 | Colgate-Palmolive Company | Aqueous oral solution |
US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
JP2627158B2 (ja) * | 1987-11-20 | 1997-07-02 | ゼリア新薬工業株式会社 | 脂溶性物質の安定な水溶液 |
JP2792005B2 (ja) * | 1988-08-11 | 1998-08-27 | 竹本油脂株式会社 | 農薬粒剤用崩壊助剤及び該崩壊助剤を含有する農薬粒剤 |
JP2792006B2 (ja) * | 1988-09-22 | 1998-08-27 | 竹本油脂株式会社 | 農薬粒剤用崩壊拡展助剤及び該崩壊拡展助剤を含有する農薬粒剤 |
EP0733358A3 (de) * | 1995-03-21 | 1998-05-20 | Novartis AG | Intravenös applizierbare Nanosuspensionen |
-
1996
- 1996-03-12 EP EP96810150A patent/EP0733358A3/de not_active Withdrawn
- 1996-03-12 EP EP96810151A patent/EP0733372A3/de not_active Withdrawn
- 1996-03-15 AU AU48095/96A patent/AU4809596A/en not_active Abandoned
- 1996-03-15 AU AU48094/96A patent/AU4809496A/en not_active Abandoned
- 1996-03-19 CA CA002172110A patent/CA2172110A1/en not_active Abandoned
- 1996-03-19 NZ NZ286207A patent/NZ286207A/en unknown
- 1996-03-19 CA CA002172111A patent/CA2172111A1/en not_active Abandoned
- 1996-03-19 IL IL11755196A patent/IL117551A0/xx unknown
- 1996-03-19 JP JP8063194A patent/JPH08268893A/ja active Pending
- 1996-03-19 JP JP8063092A patent/JPH08268915A/ja active Pending
- 1996-03-19 MX MX9601032A patent/MX9601032A/es unknown
- 1996-03-19 NZ NZ286206A patent/NZ286206A/en unknown
- 1996-03-19 IL IL11755096A patent/IL117550A0/xx unknown
- 1996-03-20 KR KR1019960007552A patent/KR960034028A/ko not_active Application Discontinuation
- 1996-03-20 KR KR1019960007541A patent/KR960033471A/ko not_active Application Discontinuation
- 1996-03-20 US US08/619,068 patent/US5726164A/en not_active Expired - Fee Related
- 1996-03-20 KR KR1019960007484A patent/KR100191221B1/ko not_active IP Right Cessation
- 1996-03-20 NO NO961136A patent/NO961136L/no unknown
- 1996-03-20 ZA ZA962248A patent/ZA962248B/xx unknown
- 1996-03-20 KR KR1019960007547A patent/KR960035462A/ko active IP Right Grant
- 1996-03-20 HU HU9600701A patent/HUP9600701A3/hu unknown
- 1996-03-20 NO NO961137A patent/NO961137L/no unknown
- 1996-03-20 KR KR1019960007485A patent/KR100191219B1/ko not_active IP Right Cessation
- 1996-03-20 KR KR1019960007540A patent/KR960033470A/ko not_active Application Discontinuation
- 1996-03-20 ZA ZA962249A patent/ZA962249B/xx unknown
- 1996-03-20 KR KR1019960007545A patent/KR100194987B1/ko not_active IP Right Cessation
- 1996-03-20 HU HU9600700A patent/HUP9600700A3/hu unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100422763B1 (ko) * | 2002-01-17 | 2004-03-12 | 주식회사 태평양 | 경피흡수 촉진 능력이 우수한 식물성 나노입자의 제조 및이를 함유하는 화장료 및 의약용 외용제 조성물 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR960033471A (ko) | 나노현탁액용 제약 담체 | |
KR950031069A (ko) | 골손실의 억제 및 혈청 콜레스테롤의 강하 방법 | |
KR960016890A (ko) | 스타우로스포린 유도체의 정맥내 투여 용액 | |
ATE172111T1 (de) | Arzneizusammensetzungen enthaltend nanokapseln | |
EA200100298A1 (ru) | ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ С РЕГУЛИРУЕМЫМ ВЫСВОБОЖДЕНИЕМ, СОДЕРЖАЩИЕ ИНГИБИТОР cGMP-ФОСФОДИЭСТЕРАЗЫ-5 | |
NO20002991L (no) | Farmasøytiske sammensetninger som inneholder en <omega>-3- fettsyreolje | |
ATE147272T1 (de) | Pharmazeutische zubereitungsformen | |
ATE270544T1 (de) | Halbfeste arzneizubereitung enthaltend isotretinoin | |
NO20000466D0 (no) | Farmasoeytisk preparat for sure, lipofile forbindelser i form av en selvemulgerende formulering | |
KR890016966A (ko) | 신규 항바이러스제 | |
KR960700061A (ko) | 니코틴 의존상태 치료를 위한 약리학적 제형 (pharmaceutical composition for treating nicotine dependence) | |
KR890003382A (ko) | 항 비루스성 화합물 | |
KR960000247A (ko) | 사이클로스포린a 함유 조성물 및 그의 제조방법 | |
HUP9802861A2 (hu) | Calendula glikozidok alkalmazása bőrsejtek túlburjánzásával kapcsolatos betegségek, így psoriasis kezelésére alkalmas gyógyászati készítmény előállítására, ezen vegyületek, valamint ezeket tartalmazó gyógyászati készítmények | |
KR970025615A (ko) | 암 전이 억제제 | |
HK1064954A1 (en) | Clear propofol compositions | |
EP0542930A1 (en) | ORAL MEDICINE CONTAINING MELATONINE. | |
HUP0004058A2 (hu) | Készítmények és eljárások biológiai membránok permeabilitásának reverzibilis növelésére | |
KR940701251A (ko) | 콜레스테롤-강하 토코페롤 동족체 | |
PT1517682E (pt) | Formulação farmacêutica compreendendo inibidor da renina não-peptídico e tensioactivo | |
KR940007001A (ko) | 새로운 n-신나모일-2-메틸-5-메톡시-3-인돌 아세트산 에스테르, 그 제조방법 및 이를 함유하는 약학적 제제 | |
EP0867181A1 (en) | Nasal melatonin composition | |
KR970706825A (ko) | 헬리코박터의 감염에 기인하는 질환의 치료제(remedy for diseases caused by infection with helicobacter) | |
KR970704463A (ko) | 스트렙토그라민 유도체, 이의 제조 방법 및 이를 함유하는 약학 조성물(streptogramine derivatives, preparation of same and pharmaceutical compositions containing same) | |
AU8008401A (en) | Amphotericin b structured emulsion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
N231 | Notification of change of applicant | ||
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |